Insight, China's Pharmaceutical Industry

Broncus Medical Secures NMPA Fast‑Track for BroncTarget COPD System, Targeting 9 Million Refractory Patients in China

Broncus Medical (HKG: 2216) announced that China’s National Medical Products Administration (NMPA) has granted fast‑track designation...

Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026

Boehringer Ingelheim and Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced a strategic clinical collaboration to evaluate a...

Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026

Thermo Fisher Scientific Inc. (NYSE: TMO) announced a strategic collaboration with NVIDIA Corporation (NASDAQ: NVDA) to jointly...

Company Deals

SciNeuro Pharmaceuticals Licenses Alzheimer’s BBB Antibody Platform to Novartis in $1.5 Billion Deal

Fineline Cube Jan 13, 2026

SciNeuro Pharmaceuticals announced a global collaboration with Novartis AG (NYSE: NVS) to advance its next‑generation amyloid...

Company Deals

CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR‑T in Solid Tumors

Fineline Cube Jan 13, 2026

CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a clinical collaboration with Dispatch Bio to evaluate DISP‑11,...

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Fineline Cube Jan 12, 2026

Noetik, an AI‑native biotech pioneering self‑supervised machine learning in cancer therapeutics, announced a five‑year strategic...

Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026

Alphamab Oncology (HKG: 9966) announced that China’s National Medical Products Administration (NMPA) has accepted its marketing...

Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026

Pfizer Inc. (NYSE: PFE) announced that Cohort 3 of the pivotal Phase 3 BREAKWATER trial met its primary...

Company Drug

Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease

Fineline Cube Jan 12, 2026

Insilico Medicine (HKG: 3696) announced that the first patient has been dosed in the BETHESDA...

Company Drug

Lynk Pharmaceuticals Reports Positive Phase III Data for Zemprocitinib in Rheumatoid Arthritis – Best‑in‑Class JAK1 Inhibitor Shows 79 % ACR20 Response

Fineline Cube Jan 12, 2026

Lynk Pharmaceuticals Co., Ltd. announced positive topline results from a pivotal Phase III trial of zemprocitinib...

Company Medical Device

Lifetech Scientific Secures NMPA Approval for G‑iliac Pro – Upgraded Iliac Branch Device for Aortic Aneurysm Repair

Fineline Cube Jan 12, 2026

Lifetech Scientific Corporation (HKG: 1302) announced that China’s National Medical Products Administration (NMPA) has granted market...

Company Deals

Mirxes Partners with Thailand’s N Health to Launch miRNA Cancer Screening

Fineline Cube Jan 12, 2026

Mirxes Holding Company Ltd, a Singapore‑headquartered RNA technology company, announced a strategic partnership with N...

Company Drug

Santen’s UPNEEQ Wins Japan Approval for Acquired Ptosis

Fineline Cube Jan 12, 2026

Santen Pharmaceutical Co., Ltd. announced that UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800) has been approved...

Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Fineline Cube Jan 12, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced an option and license agreement...

Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Fineline Cube Jan 12, 2026

Simcere Pharmaceutical Group Limited (HKG: 2096) announced plans to spin off its subsidiary Simcere Zaiming...

Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026

Nona Biosciences, a wholly‑owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a multi‑target antibody...

Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Fineline Cube Jan 12, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that the National Medical Products...

Company Drug

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Fineline Cube Jan 12, 2026

Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) announced that its subsidiary, Shanghai SPH Zhongxi Pharmaceutical...

Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026

The FDA’s Center for Biologics Evaluation and Research (CBER) announced a flexible, lifecycle‑based approach to...

Company Drug

Huadong Medicine’s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia

Fineline Cube Jan 12, 2026

Huadong Medicine Co., Ltd (SHE: 000963) announced that DR10624, a long‑acting triple‑target agonist developed by...

Insight, China's Pharmaceutical Industry

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Broncus Medical Secures NMPA Fast‑Track for BroncTarget COPD System, Targeting 9 Million Refractory Patients in China

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

SciNeuro Pharmaceuticals Licenses Alzheimer’s BBB Antibody Platform to Novartis in $1.5 Billion Deal

CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR‑T in Solid Tumors

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease

Lynk Pharmaceuticals Reports Positive Phase III Data for Zemprocitinib in Rheumatoid Arthritis – Best‑in‑Class JAK1 Inhibitor Shows 79 % ACR20 Response

Lifetech Scientific Secures NMPA Approval for G‑iliac Pro – Upgraded Iliac Branch Device for Aortic Aneurysm Repair

Mirxes Partners with Thailand’s N Health to Launch miRNA Cancer Screening

Santen’s UPNEEQ Wins Japan Approval for Acquired Ptosis

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Huadong Medicine’s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia

You Missed

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets